Biontech announces second quarter 2025 financial results and corporate update

Continued execution of biontech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mrna-based cancer immunotherapy candidates and bnt327, a bispecific antibody candidate targeting pd-l1 1 and vegf-a entered a global strategic co-development and co-commercialization collaboration with bristol myers squibb (“bms”) to jointly execute a broad clinical development program to evaluate and advance bnt327 across numerous solid tumor types announced strategic transaction to acquire curevac n.v. (“curevac”) to strengthen the research, development, manufacturing and commercialization of mrna-based cancer immunotherapy candidates presented multiple clinical updates across diversified oncology pipeline at medical meetings validating the company's oncology combination strategy approval received for new variant-adapted covid-19 vaccine by the european commission (“ec”); further launch preparation underway as recommended by regulators, with deliveries expected to be ready as early as august, subject to regulatory approval in respective markets second quarter 2025 revenues of €0.3 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.60 ($1.823) maintained strong financial position with €16.0 billion in cash, cash equivalents and security investments as of june 30, 2025; partnership with bristol myers squibb expected4 to further strengthen biontech's financial position with $1.5 billion expected to be reflected in third quarter 2025 cash position full year 2025 financial guidance reaffirmed5 conference call and webcast scheduled for august 4, 2025, at 8:00 a.m.
BNTX Ratings Summary
BNTX Quant Ranking